The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Soliqua 100/33
insulin glargine and lixisenatide · INSULIN GLARGINE 100 U/mL; LIXISENATIDE 33 ug/mL · Injection, Solution · Subcutaneous · Sanofi-Aventis U.S. LLC
NDC 00024-5761-01 · 1 SYRINGE in 1 CARTON / 3 mL in 1 SYRINGE · BLA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00024-5761-05) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$57.09per unit
middle half $56.34–$58.47 · 5,035 plans · Apr 1, 2026
Est. net of rebatesⓘ
$34.26–$42.82
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
92%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 96%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for insulin glargine and lixisenatide (injectable) in the next 90 days
sterile injectable
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · api manufacture · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA208673
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of insulin glargine and lixisenatide (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | INSULIN GLARGINE 100 U/mL; LIXISENATIDE 33 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Soliqua 100/33 — NDC 00024-5761-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00024576101.
Free to cite with attribution — see how the data is put together.